129
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP)

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon, , & ORCID Icon show all
Pages 4819-4828 | Received 31 May 2022, Accepted 16 Aug 2022, Published online: 24 Aug 2022

References

  • Chauhan S. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomed J. 2020;43(4):334–340. doi:10.1016/j.bj.2020.05.023
  • Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region. Italy. JAMA. 2020;323(16):1574–1581. doi:10.1001/jama.2020.5394
  • Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0
  • Horby P, Lim WS; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:10.1056/NEJMoa2021436
  • Gordon AC, Mouncey PR; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–1502. doi:10.1056/NEJMoa2100433
  • Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. doi:10.1056/NEJMoa2031994
  • Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the Euphrates randomized clinical trial. JAMA. 2018;320(14):1455–1463. doi:10.1001/jama.2018.14618
  • Shimizu T, Miyake T, Kitamura N, Tani M, Endo Y. Endotoxin adsorption: direct hemoperfusion with the polymyxin B-immobilized fiber column (PMX). Transfus Apher Sci. 2017;56(5):682–688. doi:10.1016/j.transci.2017.08.015
  • Ono S, Kimura A, Hiraki S, et al. Removal of increased circulating CD4+CD25+Foxp3+ regulatory T cells in patients with septic shock using hemoperfusion with polymyxin B-immobilized fibers. Surgery. 2013;153(2):262–271. doi:10.1016/j.surg.2012.06.023
  • Nishibori M, Takahashi HK, Katayama H, et al. Specific removal of monocytes from peripheral blood of septic patients by polymyxin B-immobilized filter column. Acta Med Okayama. 2009;63(1):65–69. doi:10.18926/AMO/31855
  • Ichiyasu H, Horio Y, Masunaga A, et al. Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies. Ther Adv Respir Dis. 2017;11(7):261–275. doi:10.1177/1753465817708950
  • Enomoto N, Mikamo M, Oyama Y, et al. Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm Med. 2015;15:15. doi:10.1186/s12890-015-0004-4
  • Schaller T, Hirschbühl K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. JAMA. 2020;323(24):2518–2520. doi:10.1001/jama.2020.8907
  • Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020;8(8):750–752. doi:10.1016/S2213-2600(20)30222-8
  • Kuwana T, Kinoshita K, Hirabayashi M, et al. PMX-DHP therapy for dyspnea and deoxygenation in severe COVID-19 pneumonia: a case series. Infect Drug Resist. 2021;14:1305–1310. doi:10.2147/IDR.S299023
  • Katagiri D, Ishikane M, Asai Y, et al. Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J Clin Apher. 2021;36(3):313–321. doi:10.1002/jca.21861
  • De Rosa S, Cutuli SL, Ferrer R, Antonelli M, Ronco C; COVID-19 EUPHAS2 Collaborative Group. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: case series from EUPHAS2 registry. Artif Organs. 2021;45(6):E187–E194. doi:10.1111/aor.13900
  • Schalekamp S, Huisman M, van Dijk RA, et al. Model-based prediction of critical illness in hospitalized patients with COVID-19. Radiology. 2021;298(1):E46–E54. doi:10.1148/radiol.2020202723
  • Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793–1800. doi:10.1097/00003246-199811000-00016
  • Shekar K, Badulak J, Peek G, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. ASAIO J. 2020;66(7):707–721. doi:10.1097/MAT.0000000000001193
  • Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233–1244. doi:10.1016/S2213-2600(20)30404-5
  • Naik NB, Puri GD, Kajal K, et al. High-dose dexamethasone versus tocilizumab in moderate to severe COVID-19 pneumonia: a randomized controlled trial. Cureus. 2021;13(12):e20353. doi:10.7759/cureus.20353
  • Akbari H, Tabrizi R, Lankarani KB, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Life Sci. 2020;258:118167. doi:10.1016/j.lfs.2020.118167
  • Oishi K, Mimura-Kimura Y, Miyasho T, et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine. 2013;61(1):84–89. doi:10.1016/j.cyto.2012.08.032
  • Liu Q, Wang RS, Qu GQ, et al. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020;36(1):21–23. doi:10.12116/j.issn.1004-5619.2020.01.005
  • Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi. 2020;49(5):411–417. doi:10.3760/cma.j.cn112151-20200312-00193
  • Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345–1355. doi:10.1001/jamainternmed.2020.3539
  • Eisner MD, Parsons P, Matthay MA, Ware L, Greene K; Acute Respiratory Distress Syndrome Network. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003;58(11):983–988. doi:10.1136/thorax.58.11.983
  • Tong M, Xiong Y, Zhu C, et al. Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity. BMC Infect Dis. 2021;21(1):737. doi:10.1186/s12879-021-06447-3
  • Lim ZJ, Subramaniam A, Ponnapa Reddy M, et al. Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis. Am J Respir Crit Care Med. 2021;203(1):54–66. doi:10.1164/rccm.202006-2405OC
  • Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955. doi:10.1371/journal.pone.0241955